Page 284 - Drug Class Review
P. 284
Page 172 of 205
Drug Effectiveness Review Project
Alzheimer Drugs Authors: Morganroth et al. 85 Year: 2002 Country: US eResearch Technology, Philadelphia, PA and Novartis Pharmaceuticals Corporation, East Hanover, NJ Study design: Pooled data-analysis Number of patients: 2,791 To determine if RIV has adverse cardiac effects by analysis of recorded ECGs Four phase III clinical trials in AD patients reported in: Corey-Bloom et al. 1998; Rosler et al. 1999; Schneider et al. 1998 1998 Four placebo-controlled trials of RIV (26 weeks) at outpatient research centers in 10 countries; doses of 1- 12 mg/day titrated over 7 to 12 week
Final Report Update 1 Adverse Events STUDY: FUNDING: DESIGN: AIMS OF REVIEW: STUDIES INCLUDED IN META-ANALYSIS TIME PERIOD COVERED: CHARACTERISTICS OF INCLUDED STUDIES: CHARACTERISTICS OF INCLUDED POPULATIONS: Alzheimer's Drugs
